Cargando…
Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope
CD4(+) T-cells recognize peptide antigens, in the context of human leukocyte antigen (HLA) class II molecules (HLA-II), which through peptide-flanking residues (PFRs) can extend beyond the limits of the HLA binding. The role of the PFRs during antigen recognition is not fully understood; however, re...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937582/ https://www.ncbi.nlm.nih.gov/pubmed/31619516 http://dx.doi.org/10.1074/jbc.RA119.009437 |
_version_ | 1783483898957660160 |
---|---|
author | MacLachlan, Bruce J. Dolton, Garry Papakyriakou, Athanasios Greenshields-Watson, Alexander Mason, Georgina H. Schauenburg, Andrea Besneux, Matthieu Szomolay, Barbara Elliott, Tim Sewell, Andrew K. Gallimore, Awen Rizkallah, Pierre Cole, David K. Godkin, Andrew |
author_facet | MacLachlan, Bruce J. Dolton, Garry Papakyriakou, Athanasios Greenshields-Watson, Alexander Mason, Georgina H. Schauenburg, Andrea Besneux, Matthieu Szomolay, Barbara Elliott, Tim Sewell, Andrew K. Gallimore, Awen Rizkallah, Pierre Cole, David K. Godkin, Andrew |
author_sort | MacLachlan, Bruce J. |
collection | PubMed |
description | CD4(+) T-cells recognize peptide antigens, in the context of human leukocyte antigen (HLA) class II molecules (HLA-II), which through peptide-flanking residues (PFRs) can extend beyond the limits of the HLA binding. The role of the PFRs during antigen recognition is not fully understood; however, recent studies have indicated that these regions can influence T-cell receptor (TCR) affinity and pHLA-II stability. Here, using various biochemical approaches including peptide sensitivity ELISA and ELISpot assays, peptide-binding assays and HLA-II tetramer staining, we focused on CD4(+) T-cell responses against a tumor antigen, 5T4 oncofetal trophoblast glycoprotein (5T4), which have been associated with improved control of colorectal cancer. Despite their weak TCR-binding affinity, we found that anti-5T4 CD4(+) T-cells are polyfunctional and that their PFRs are essential for TCR recognition of the core bound nonamer. The high-resolution (1.95 Å) crystal structure of HLA-DR1 presenting the immunodominant 20-mer peptide 5T4(111–130), combined with molecular dynamic simulations, revealed how PFRs explore the HLA-proximal space to contribute to antigen reactivity. These findings advance our understanding of what constitutes an HLA-II epitope and indicate that PFRs can tune weak affinity TCR–pHLA-II interactions. |
format | Online Article Text |
id | pubmed-6937582 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Society for Biochemistry and Molecular Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-69375822020-01-02 Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope MacLachlan, Bruce J. Dolton, Garry Papakyriakou, Athanasios Greenshields-Watson, Alexander Mason, Georgina H. Schauenburg, Andrea Besneux, Matthieu Szomolay, Barbara Elliott, Tim Sewell, Andrew K. Gallimore, Awen Rizkallah, Pierre Cole, David K. Godkin, Andrew J Biol Chem Immunology CD4(+) T-cells recognize peptide antigens, in the context of human leukocyte antigen (HLA) class II molecules (HLA-II), which through peptide-flanking residues (PFRs) can extend beyond the limits of the HLA binding. The role of the PFRs during antigen recognition is not fully understood; however, recent studies have indicated that these regions can influence T-cell receptor (TCR) affinity and pHLA-II stability. Here, using various biochemical approaches including peptide sensitivity ELISA and ELISpot assays, peptide-binding assays and HLA-II tetramer staining, we focused on CD4(+) T-cell responses against a tumor antigen, 5T4 oncofetal trophoblast glycoprotein (5T4), which have been associated with improved control of colorectal cancer. Despite their weak TCR-binding affinity, we found that anti-5T4 CD4(+) T-cells are polyfunctional and that their PFRs are essential for TCR recognition of the core bound nonamer. The high-resolution (1.95 Å) crystal structure of HLA-DR1 presenting the immunodominant 20-mer peptide 5T4(111–130), combined with molecular dynamic simulations, revealed how PFRs explore the HLA-proximal space to contribute to antigen reactivity. These findings advance our understanding of what constitutes an HLA-II epitope and indicate that PFRs can tune weak affinity TCR–pHLA-II interactions. American Society for Biochemistry and Molecular Biology 2019-12-27 2019-10-16 /pmc/articles/PMC6937582/ /pubmed/31619516 http://dx.doi.org/10.1074/jbc.RA119.009437 Text en © 2019 MacLachlan et al. Author's Choice—Final version open access under the terms of the Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0) . |
spellingShingle | Immunology MacLachlan, Bruce J. Dolton, Garry Papakyriakou, Athanasios Greenshields-Watson, Alexander Mason, Georgina H. Schauenburg, Andrea Besneux, Matthieu Szomolay, Barbara Elliott, Tim Sewell, Andrew K. Gallimore, Awen Rizkallah, Pierre Cole, David K. Godkin, Andrew Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope |
title | Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope |
title_full | Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope |
title_fullStr | Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope |
title_full_unstemmed | Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope |
title_short | Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope |
title_sort | human leukocyte antigen (hla) class ii peptide flanking residues tune the immunogenicity of a human tumor-derived epitope |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937582/ https://www.ncbi.nlm.nih.gov/pubmed/31619516 http://dx.doi.org/10.1074/jbc.RA119.009437 |
work_keys_str_mv | AT maclachlanbrucej humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope AT doltongarry humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope AT papakyriakouathanasios humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope AT greenshieldswatsonalexander humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope AT masongeorginah humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope AT schauenburgandrea humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope AT besneuxmatthieu humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope AT szomolaybarbara humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope AT elliotttim humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope AT sewellandrewk humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope AT gallimoreawen humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope AT rizkallahpierre humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope AT coledavidk humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope AT godkinandrew humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope |